IOVANCE BIOTHERAPEUTICS APPOINTS NEW CHIEF MEDICAL OFFICER

Ticker: IOVA · Form: 8-K · Filed: Aug 9, 2024 · CIK: 1425205

Iovance Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyIovance Biotherapeutics, Inc. (IOVA)
Form Type8-K
Filed DateAug 9, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Key Dollar Amounts$0.000041666
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, personnel-change, biotech

Related Tickers: BMY

TL;DR

IOVANCE just hired a new CMO from Bristol Myers Squibb, starting Aug 12th.

AI Summary

On August 8, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing the appointment of Dr. Frederick "Fritz" Morgan as Chief Medical Officer, effective August 12, 2024. Dr. Morgan previously served as Senior Vice President and Head of Oncology Clinical Development at Bristol Myers Squibb.

Why It Matters

The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's clinical development strategy and future drug pipeline.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategic direction or potential challenges in clinical development.

Key Players & Entities

  • IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
  • Dr. Frederick "Fritz" Morgan (person) — Newly appointed Chief Medical Officer
  • August 12, 2024 (date) — Effective date of appointment
  • Bristol Myers Squibb (company) — Dr. Morgan's previous employer

FAQ

Who has been appointed as the new Chief Medical Officer for IOVANCE BIOTHERAPEUTICS, INC.?

Dr. Frederick "Fritz" Morgan has been appointed as the new Chief Medical Officer.

When is the effective date for Dr. Morgan's new role?

Dr. Morgan's appointment is effective August 12, 2024.

What was Dr. Morgan's previous role?

Dr. Morgan previously served as Senior Vice President and Head of Oncology Clinical Development at Bristol Myers Squibb.

What is the filing date of this 8-K report?

The filing date of this 8-K report is August 9, 2024.

What is the state of incorporation for IOVANCE BIOTHERAPEUTICS, INC.?

IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.

Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 9.3 · Accepted 2024-08-09 17:16:12

Key Financial Figures

  • $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke

Filing Documents

01

Item 8.01 Other Events. On August 8, 2024, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation – August 8, 2024 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 9, 2024 Iovance Biotherapeutics, Inc. By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and President, and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.